NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.56 -1.01 (-1.30%) GOLD FUTURES
2,336.80 -56.10 (-2.34%) DOW
39,083.65 -587.39 (-1.48%) Bitcoin GBP
52,806.69 -1,927.66 (-3.52%)
Aptorum Group Limited (APM)
| Previous close | 4.0500 |
| Open | 4.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.9000 - 4.1100 |
| 52-week range | 1.3500 - 17.4900 |
| Volume | |
| Avg. volume | 2,454,216 |
| Market cap | 21.994M |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
NEW YORK & LONDON, April 30, 2024--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments.
- Business Wire
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
NEW YORK & LONDON, March 06, 2024--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company ("Aptorum"), and privately-held YOOV Group Holding Ltd. ("YOOV") jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"). The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of directors, the "Board"), respectively. If the Merger Agreement is approved by Apto
- Business Wire
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
NEW YORK & LONDON, December 22, 2023--Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023.
